ERBB2 and breast cancer: In addition to the direct targeting effects on HER2-positive cells, it has been reported that trastuzumab is able to induce a long-lasting immune response in patients with BC (193), but it is still unclear whether trastuzumab has direct effects on Treg immune subsets.